Portal de investigação
Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Brandao, M
- Morais, S
- Lopes-Conceiçao, L
- Araújo, N
- Dias, T
- Pereira, D
- Borges, M
- Pereira, S
Unidades de investigação
Abstract
Background The cost of breast cancer care rises with higher stage at diagnosis; however, there are no real-world data regarding the cost of care according to breast cancer subtypes. This study aimed to estimate direct medical costs for early breast cancer care in the first 3 years after diagnosis according to subtype and stage, using patient-level data. Methods Women with newly diagnosed stage I-III breast cancer, admitted in 2012 to a Portuguese cancer centre were prospectively followed within the NEON-BC cohort. The use of health resources was obtained from each patient's clinical and administrative records and costs were computed. Tumours were classified into the classic subtypes (hormone receptor-positive (HR+)/HER2-; HER2-positive (HER2+); triple-negative breast cancer (TNBC)) and surrogate intrinsic subtypes (luminal A-like; luminal B-like; HER2 enriched; basal like). Results A total of 703 patients were included: 48.9% had stage I, 35.8% stage II and 15.2% stage III breast cancer; 76.4% had HR+/HER2-, 15.9% HER2+ and 7.7% TNBC. Median cost of care was euro9215/patient in stage I, euro13 019/patient in stage II and euro15 011/patient in stage III and euro10 540/patient in HR+/HER2-, euro11 224/patient in TNBC and euro41 513/patient in HER2+ breast cancer. Systemic therapy accounted for 69.2% of the cost of care among patients with HER2+, 12.0% among HR+/HER2- and 7.5% among TNBC patients. Similar differences were observed across surrogate intrinsic subtypes. Conclusions The cost of early breast cancer care was mainly driven by the tumour subtype and, to a lesser extent, by stage. The median cost of care was fourfold higher among patients with HER2+ tumours compared with those with HR+/HER2- and TNBC. These data provide information for the economic evaluation of innovative treatments for early breast cancer and highlight the weight that targeted systemic therapy might have in the overall cost of care among patients with early breast cancer.
Dados da publicação
- ISSN/ISSNe:
- 2059-7029, 2059-7029
- Tipo:
- Article
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
ESMO Open Elsevier BV
Citações Recebidas na Web of Science: 13
Citações Recebidas na Scopus: 16
Documentos
- Não há documentos
Filiações
Keywords
- breast neoplasms; health care costs; longitudinal studies; triple negative breast neoplasms
Financiamento
Proyectos asociados
RISK AND SURVIVAL OF GASTRIC CANCER RELATES SECOND PRIMARY TUMOURS: A COMPETING RISKS FRAMEWORK
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2019
Citar a publicação
Brandao M,Morais S,Lopes L,Fontes F,Araújo N,Dias T,Pereira D,Borges M,Pereira S,Lunet N. Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype. ESMO Open. 2020. 5. (6):e000984. IF:6,540. (1).
